Atea Pharmaceuticals, Inc. Common Stock
AVIRAtea Pharmaceuticals, Inc. (AVIR) is a biotechnology company focused on developing innovative antiviral therapies for infectious diseases. The company leverages its proprietary research platform to discover and advance new treatments for viral illnesses, with an emphasis on respiratory viruses such as COVID-19. Atea collaborates with partners and clinical organizations to accelerate the development of its pipeline candidates.
Company News
Atea Pharmaceuticals announced Phase 1 results demonstrating that its fixed-dose combination regimen of bemnifosbuvir and ruzasvir (BEM/RZR) for hepatitis C virus treatment has a low risk of drug-drug interactions with commonly used medications like omeprazole and rosuvastatin. The company also presented preclinical data showing AT-587, a potenti...
Atea Pharmaceuticals announced preclinical results showing AT-587 and AT-2490 are potent inhibitors of Hepatitis E Virus (HEV), demonstrating 30-150 fold greater potency compared to sofosbuvir and ribavirin. The company plans to initiate Phase 1 clinical trials for AT-587 mid-2026, addressing an unmet medical need as no antivirals are currently a...
Atea Pharmaceuticals presented modeling data showing their combination drug regimen of bemnifosbuvir and ruzasvir could potentially provide a short-duration, highly effective treatment for hepatitis C virus, with near-complete viral inhibition and a modeled cure time of 7-8 weeks.
Atea Pharmaceuticals will host a conference call on November 12, 2025, to discuss third quarter financial results and provide a business update, focusing on their antiviral drug development platform and HCV treatment research.
Atea Pharmaceuticals will host a conference call on August 7, 2025, to discuss second quarter 2025 financial results and provide a business update, focusing on their HCV treatment development program.
